Key Highlights

● Stryker traded at $277.35 pre-market, down 11.03%, after its third-quarter report.

● Net sales rose 7.7% to about $6.5 billion, but the CEO said results fell short.

● Full-year adjusted EPS guidance is now $14.80 to $14.90.

● A $293 million Goodwill Impairment weighed on GAAP EPS, which fell 11.7%.

Stryker (NYSE:SYK) is one of the biggest losers heading into Friday's session. The medical device maker was trading at $277.35 in pre-market action, down 11.03%, as of an 8:23 a.m. ET market snapshot. Another source showed a similar decline of 11.15%.

The sell-off follows third-quarter results released after Thursday's close. The headline growth looked solid: net sales rose 7.7% to about $6.5 billion, all of it organic, and adjusted Earnings Per Share increased 10.3% to $3.52. CEO Kevin Lobo was blunt, though. "While, in absolute terms, this reflected good overall performance, it did fall short of our expectations," he said in the earnings release.

For a company that investors usually treat as a reliable compounder, that admission matters as much as the numbers.

Guidance resets the bar

Stryker said it was "updating" its full-year 2026 outlook. It now expects organic net sales growth of 6.5% to 7.0% and adjusted EPS of $14.80 to $14.90. The release didn't give the prior ranges, but one report said the new EPS range sits below the $14.95 consensus and the organic growth range falls short of the roughly 8.2% analysts had expected.

GAAP results were weaker still. GAAP EPS fell 11.7% to $1.96, partly because of a $293 million goodwill impairment, equal to $0.76 per share, that Stryker excluded from adjusted results. The release didn't say which Business the charge relates to.

The segment detail shows mixed results. Endoscopy was a standout, with sales up 13.9% to $1.02 billion. Knees grew only 1.1% to $635 million, and hips declined 1.0% to $453 million. U.S. sales grew 8.3%, while international sales rose 5.7%.

Automated market notes linked the miss to slower hip and knee procedures and disruption from a software implementation. Stryker's release doesn't confirm those explanations, so they should be read as unconfirmed. The weak hip and knee figures do suggest orthopaedics lagged, though.

Stryker kept returning capital, buying back $1.0 billion of stock in the quarter. The board added $3.0 billion to its repurchase authorization in October.

What it means for the S&P 500, and the bull case

Stryker is an S&P 500 member and one of the largest U.S. medical technology companies, making implants, surgical equipment and neurotechnology products. Its stumble comes a day after health care was the S&P 500's best sector, with the Health Care Select Sector SPDR (XLV) rising about 2.4% to a record on Thursday, led by Eli Lilly (NYSE:LLY).

That rotation into defensives helped the sector, but Stryker's drop shows investors will still punish disappointments there. The broader tape isn't helping. S&P 500 futures were down roughly 1.1% early Friday as Amazon (NASDAQ:AMZN) and Intel (NASDAQ:INTC) weighed on tech, and the 10-year Treasury Yield is still near 5%.

Lobo argued that "the underlying fundamentals of the business remain strong," and said he expects "a solid performance in Q4 and good momentum heading into 2027." By most standards, 7.7% organic growth with double-digit adjusted earnings growth is a healthy quarter.

The main risk is that investors start to doubt Stryker's premium valuation if the orthopaedics slowdown lasts or the guidance trim turns into a pattern.

What to watch next

At the open, watch whether the stock holds near the pre-market low of roughly $277 or the selling deepens. More analyst moves are likely: one brokerage has already downgraded the stock. Watch for management commentary on hip and knee Demand and on the cause of the impairment. Stryker's next quarterly report, covering the fourth quarter and the 2027 outlook, has not yet been scheduled.